Core Viewpoint - Corning Jereh Pharmaceutical-B (09966.HK) expects to report a profit of no less than RMB 20 million for the six months ending June 30, 2025, compared to a loss of approximately RMB 44.9 million in the same period of 2024, indicating a turnaround from loss to profit driven by milestone revenues from three licensing collaborations and sales revenue from commercialized products [1] Financial Performance - The company anticipates a profit of at least RMB 20 million for the upcoming reporting period [1] - In contrast, the previous year’s corresponding period showed a loss of around RMB 44.9 million [1] Revenue Drivers - The turnaround to profitability is attributed to milestone income from three licensing agreements [1] - Additionally, revenue from the sales of commercialized products contributed to the positive financial outlook [1]
【盈喜】康宁杰瑞制药-B(09966.HK)料中期转亏为盈 利润不少于2000万元